Novartis calls in Shearman on £4.4bn generics deal
Legal Week reports
Shearman & Sterling has scored the lead role on pharmaceutical giant Novartis’ $8.3bn (£4.4bn) acquisition of German drug manufacturer Hexal and a stake in US Eon Labs – securing what promises to be one of the biggest European deals of the year.
This premium content is reserved for
Legal Week Subscribers.
Subscribe today and get 10% off.
A PREMIUM SUBSCRIPTION PROVIDES:
- Trusted insight, news and analysis from the UK and across the globe
- Connections to senior business lawyers within the leading law firms and legal departments
- Optimized access on all of your devices: desktop, tablet and mobile
- Complete access to the site's full archive of more than 56,000 articles
Already have an account? Sign In Now